Cargando…

LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders

Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as ver...

Descripción completa

Detalles Bibliográficos
Autores principales: Klemp, Henry Gerd, Kettwig, Matthias, Streit, Frank, Gärtner, Jutta, Rosewich, Hendrik, Krätzner, Ralph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226985/
https://www.ncbi.nlm.nih.gov/pubmed/34072483
http://dx.doi.org/10.3390/metabo11060347
_version_ 1783712417601028096
author Klemp, Henry Gerd
Kettwig, Matthias
Streit, Frank
Gärtner, Jutta
Rosewich, Hendrik
Krätzner, Ralph
author_facet Klemp, Henry Gerd
Kettwig, Matthias
Streit, Frank
Gärtner, Jutta
Rosewich, Hendrik
Krätzner, Ralph
author_sort Klemp, Henry Gerd
collection PubMed
description Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as very long-chain fatty acids (VLCFA), which can be inconspicuous in milder and atypical cases. Holistic metabolomics studies revealed several potentially new biomarkers for peroxisomal disorders for advanced laboratory diagnostics including atypical cases. However, establishing these new markers is a major challenge in routine diagnostic laboratories. We therefore investigated whether the commercially available AbsoluteIDQ p180 kit (Biocrates Lifesciences), which utilizes flow injection and liquid chromatography mass spectrometry, may be used to reproduce some key results from previous global metabolomics studies. We applied it to serum samples from patients with mutations in peroxisomal target genes PEX1, ABCD1, and the HSD17B4 gene. Here we found various changes in sphingomyelins and lysophosphatidylcholines. In conclusion, this kit can be used to carry out extended diagnostics for peroxisomal disorders in routine laboratories, even without access to a metabolomics unit.
format Online
Article
Text
id pubmed-8226985
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-82269852021-06-26 LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders Klemp, Henry Gerd Kettwig, Matthias Streit, Frank Gärtner, Jutta Rosewich, Hendrik Krätzner, Ralph Metabolites Article Peroxisomes are central hubs for cell metabolism and their dysfunction is linked to devastating human disorders, such as peroxisomal biogenesis disorders and single peroxisomal enzyme/protein deficiencies. For decades, biochemical diagnostics have been carried out using classical markers such as very long-chain fatty acids (VLCFA), which can be inconspicuous in milder and atypical cases. Holistic metabolomics studies revealed several potentially new biomarkers for peroxisomal disorders for advanced laboratory diagnostics including atypical cases. However, establishing these new markers is a major challenge in routine diagnostic laboratories. We therefore investigated whether the commercially available AbsoluteIDQ p180 kit (Biocrates Lifesciences), which utilizes flow injection and liquid chromatography mass spectrometry, may be used to reproduce some key results from previous global metabolomics studies. We applied it to serum samples from patients with mutations in peroxisomal target genes PEX1, ABCD1, and the HSD17B4 gene. Here we found various changes in sphingomyelins and lysophosphatidylcholines. In conclusion, this kit can be used to carry out extended diagnostics for peroxisomal disorders in routine laboratories, even without access to a metabolomics unit. MDPI 2021-05-29 /pmc/articles/PMC8226985/ /pubmed/34072483 http://dx.doi.org/10.3390/metabo11060347 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Klemp, Henry Gerd
Kettwig, Matthias
Streit, Frank
Gärtner, Jutta
Rosewich, Hendrik
Krätzner, Ralph
LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title_full LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title_fullStr LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title_full_unstemmed LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title_short LC-MS Based Platform Simplifies Access to Metabolomics for Peroxisomal Disorders
title_sort lc-ms based platform simplifies access to metabolomics for peroxisomal disorders
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226985/
https://www.ncbi.nlm.nih.gov/pubmed/34072483
http://dx.doi.org/10.3390/metabo11060347
work_keys_str_mv AT klemphenrygerd lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders
AT kettwigmatthias lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders
AT streitfrank lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders
AT gartnerjutta lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders
AT rosewichhendrik lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders
AT kratznerralph lcmsbasedplatformsimplifiesaccesstometabolomicsforperoxisomaldisorders